Literature DB >> 34179027

Infection Rate and Outcomes of Watchman Devices: Results from a Single-Center 14-Year Experience.

Robert C Ward1, Trevon McGill2, Fadi Adel2, Shiva Ponamgi3, Samuel J Asirvatham1, Larry M Baddour1,4, David R Holmes1, Daniel C DeSimone1,4, Christopher V DeSimone1.   

Abstract

The Watchman device (WD) is a commonly used alternative strategy to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation who have an increased bleeding risk. There are rare case reports of WD-related infection. Currently, there is no formal study that has systematically evaluated the incidence and outcomes WD-related infections. The objective of this study was to evaluate the incidence, risk factors, and outcomes for WD-associated infections in a single-center cohort over a 14-year period. All patients who underwent WD implantation over a 14-year study period (July 2004 through December 2018) comprised our cohort. Baseline characteristics, procedural data, and postimplantation events were identified through a retrospective chart review. Primary study outcomes included WD-related infection, other cardiovascular device-related infection, bacteremia, and mortality. A total of 181 patients (119 males; 65.7%) with a mean age of 75 years at implantation were included in the analysis. A total of 534.7 patient years of follow-up was accrued, with an average of 2.9 years per patient. The most common indications for implantation included gastrointestinal bleeding (56 patients; 30.9%) and intracerebral bleeding (51 patients; 28.2%). During the follow-up period, 37 (20.4%) patients died. Six developed evidence of bacteremia. Only 1 developed an implantable cardioverter defibrillator infection that required a complete system extraction. None of the cohort developed a WD-related device infection during the study period. We concluded that there is a low risk of WD-related infection even in the setting of a blood stream infection.
Copyright © 2021 by S. Karger AG, Basel.

Entities:  

Keywords:  Bacteremia; Endocarditis; Watchman device

Year:  2021        PMID: 34179027      PMCID: PMC8215937          DOI: 10.1159/000516400

Source DB:  PubMed          Journal:  Biomed Hub        ISSN: 2296-6870


  8 in total

1.  Left atrial appendage obliteration: mechanisms of healing and intracardiac integration.

Authors:  Robert S Schwartz; David R Holmes; Robert A Van Tassel; Robert Hauser; Timothy D Henry; Michael Mooney; Ray Matthews; Shephal Doshi; Russell M Jones; Renu Virmani
Journal:  JACC Cardiovasc Interv       Date:  2010-08       Impact factor: 11.195

2.  Transesophageal echocardiographic diagnosis of left atrial appendage occluder device infection.

Authors:  Taiyeb M Khumri; Joseph B Thibodeau; Michael L Main
Journal:  Eur J Echocardiogr       Date:  2007-08-07

3.  Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High-Risk Patients With Atrial Fibrillation.

Authors:  Pavel Osmancik; Dalibor Herman; Petr Neuzil; Pavel Hala; Milos Taborsky; Petr Kala; Martin Poloczek; Josef Stasek; Ludek Haman; Marian Branny; Jan Chovancik; Pavel Cervinka; Jiri Holy; Tomas Kovarnik; David Zemanek; Stepan Havranek; Vlastimil Vancura; Jan Opatrny; Petr Peichl; Petr Tousek; Veronika Lekesova; Jiri Jarkovsky; Martina Novackova; Klara Benesova; Petr Widimsky; Vivek Y Reddy
Journal:  J Am Coll Cardiol       Date:  2020-06-30       Impact factor: 24.094

4.  New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Duke Endocarditis Service.

Authors:  D T Durack; A S Lukes; D K Bright
Journal:  Am J Med       Date:  1994-03       Impact factor: 4.965

5.  5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials.

Authors:  Vivek Y Reddy; Shephal K Doshi; Saibal Kar; Douglas N Gibson; Matthew J Price; Kenneth Huber; Rodney P Horton; Maurice Buchbinder; Petr Neuzil; Nicole T Gordon; David R Holmes
Journal:  J Am Coll Cardiol       Date:  2017-11-04       Impact factor: 24.094

6.  Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial.

Authors:  Lucas V Boersma; Hueseyin Ince; Stephan Kische; Evgeny Pokushalov; Thomas Schmitz; Boris Schmidt; Tommaso Gori; Felix Meincke; Alexey Vladimir Protopopov; Timothy Betts; David Foley; Horst Sievert; Patrizio Mazzone; Tom De Potter; Elisa Vireca; Kenneth Stein; Martin W Bergmann
Journal:  Heart Rhythm       Date:  2017-05-31       Impact factor: 6.343

7.  Convexity Subarachnoid Hemorrhage, Pseudomonas Aeruginosa (PA) Infective Endocarditis and Left Atrial Appendage Occluder (LAAO) Device Infection. A Case Report.

Authors:  Monique Boukobza; Ibtissem Smaali; Xavier Duval; Jean-Pierre Laissy
Journal:  Open Neuroimag J       Date:  2017-05-22

8.  Transesophageal Echocardiography to Diagnose Watchman Device Infection.

Authors:  Joseph Jensen; Christina Thaler; Retu Saxena; Domenico Calcaterra; Jason Sanchez; Quirino Orlandi; Kevin M Harris
Journal:  CASE (Phila)       Date:  2020-02-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.